Annual Report 2005 - Boehringer Ingelheim

More documents

Recommendations

Info

Protection around the clock “In treating hypertension, the early morning hours are critical, as blood pressure is known to surge at that time. This surge corresponds to a sharp increase in the risk of having a heart attack or stroke. Studies have shown an estimated 40 % more people suffer a heart attack and 50 % more people suffer a stroke between 6 a.m. and 12 noon,” says Professor Bryan Williams, University of Leicester and lead investigator of the prisma studies. micardis® (telmisartan), Boehringer Ingelheim’s successful, highly efficacious drug for treating essential hypertension, offers 24-hour blood pressure control, and also provides superior blood pressure lowering compared to ramipril in the early hours. It is being evaluated for its potential to protect end-organs, such as the kidneys or the brain, as well as the potential to delay the onset of diabetes II in patients with increased risk, in the ontarget trial. Systolic blood pressure (in mmHg) in relation to time (wakening hours) (0 = wake-up time) 160 150 140 130 -4 -2 0 2 4 6 8 10 12 14 16 18 hours Boehringer Ingelheim A n n u A l R e p o R t 2 0 0 5 micardis® has the longest half-life in the ARB class, providing effective blood pressure control over 24 hours with a once daily dosage, including the early morning hours when blood pressure surges. At this critical time of day, it delivers powerful blood pressure reductions. micardis®/micardisplus® posted net sales of EUR 724 million in 2005, representing growth of 27 % and making it our third biggest BPM product. Having grown above the market average for anti- hypertensives (34 %), its global market share improved to 7.6 %. In the protection programme of clinical trials with micardis®, five trials versus main competi- tors have provided new important clinical data for micardis® and micardisplus® in hypertension, showing clear clinical superiority over ramipril, losartan, valsartan, and amlodipine + HCTZ. The detail study, published in the New England Jour- nal of Medicine in November 2004 in diabetic nephropathy has put micardis® in the map of nephro-protection. The trendy study reported in major congresses in 2005 supported the nephro- protective benefits of micardis® and three additional renal trials will consolidate the profile of the brand in this area in 2006. The landmark trials ontarget (in patients of high cardiovascular risk, with 31,700 randomised patients) and profess® (in patients with previous stroke with 15,000 patients already recruited), aiming to prove the cardio and cerebro-vascular protection properties of micardis®, are proceed- ing on schedule. Results of these trials are expected in 2008. The good acceptance of the product in 2005 provide an excellent platform to put micardis® on track to become another blockbuster. For additional information please visit our websites at www.micardis.com / www.ontarget-micardis.com Every year, approximately three million people worldwide suffer from acute myocardial infarction (AMI), or heart attack. However, only about 47 % are diagnosed and treated. About 53 % are
either not recognised or are beyond treatment. The most important factor for a successful treatment of AMI is time to treatment. Thrombolytic therapy, established as one of the most successful modern AMI treatment options, is easy to apply, available in all hospitals and considered safe in view of the serious nature of the disease. The Stroke Lysis Box from Boehringer Ingelheim enables hospital emergency departments to provide rapid clot-busting treatment. actilyse® (alteplase), is indicated for the thrombolytic treatment in AMI as well as in thrombolytic treatment in acute massive pulmonary embolism with haemodynamic instability. It has also a conditional license for the treatment of acute ischemic stroke (see below). metalyse® (tenecteplase), the only thrombolytic to be administered as single shot injection, is also registered for the thrombolytic treatment in AMI for patients, in whom a coronary intervention cannot be performed within 90 minutes of onset. With its ease of administration, metalyse® is very well-suited for pre-hospital and in-hospital thrombolysis to keep the time from onset of symptoms to effective treatment as short as possible. Both products continued to be leaders in their class and posted combined net sales of EUR 151 million, giving a 57.7 % market share in this combined class of fibrinolytics. Telemedicine helps stroke victims Acute ischaemic stroke is caused by blood clots in the brain and requires urgent specialist attention. However, only 30 % of acute stroke patients reach hospital within the first three hours. Particularly those in rural areas do not always have access to specialist care. New technologies can link rural hospitals with specialist centres. Remote patient interviewing, data transmission and video- conferencing are available 24 hours a day to all hospitals linked in the network. The benefit to the patients is twofold: they now have access to this modern treatment and the treatment is started by very experienced people. This allows a greater proportion of acute stroke patients to be assessed for thrombolysis with Boehringer Ingelheim’s actilyse® (alteplase), the only medication available for the treatment of acute stroke. Photo: Lennart Nilsson Prescription Medicines
Page 1 and 2: Value through Innovation Annual Rep
Page 3 and 4: Contents 2 The Shareholders’ Pers
Page 5 and 6: Value through Innovation Our vision
Page 7 and 8: of innovative medications. Our expe
Page 9 and 10: countries since 2000 encourages us
Page 11: Shareholders’ Committee Dr Heribe
Page 14 and 15: 10 Our commitment We have committed
Page 16 and 17: 1 For our neighbours We are fundame
Page 18 and 19: 1 For our people To achieve our cor
Page 20 and 21: 1 We foster good leadership at all
Page 22 and 23: 1 For our environment In all our ac
Page 24 and 25: 0 Assessments to date show that our
Page 27 and 28: Our R&D drive Holger Pfister has be
Page 29 and 30: New data presented at the 10th Euro
Page 31 and 32: Thanks to new treatments and innova
Page 33 and 34: Laboratory assistants at our Qualit
Page 35 and 36: In addition, our discovery efforts
Page 37 and 38: the age of 65 combined with an agin
Page 39 and 40: Clinical development and registrati
Page 41 and 42: increase the planned patient number
Page 43: Business Development Our Businesses
Page 46 and 47: “spiriva® has obviously improved
Page 48 and 49: Prescription Medicines Boehringer I
Page 52 and 53: Stroke treatment and prevention Str
Page 54 and 55: 0 Serotonin and norepinephrine also
Page 56 and 57: Rheumatologic diseases Osteoarthrit
Page 58 and 59: Asia, Australasia, Africa In all ma
Page 60: Consumer Health Care Let’s talk a
Page 63 and 64: Gentle and effective dulcolax® for
Page 65 and 66: health market. With sales of almost
Page 67 and 68: is critical
Page 69 and 70: at the end of the 1970s with the ma
Page 71 and 72: Moreover, for Boehringer Ingelheim
Page 73 and 74: Pioneering college course in biotec
Page 75 and 76: heartWhen her Labrador Buster fell
Page 77 and 78: According to the American Veterinar
Page 79 and 80: Cattle There were two highly gratif
Page 81 and 82: Group Management Report
Page 83 and 84: and strength of the group. The grea
Page 85 and 86: cymbalta®, the anti-depressive in-
Page 87 and 88: Components of growth in net sales (
Page 89 and 90: Worldwide growth was achieved by th
Page 91 and 92: Liquid assets declined by 12 % comp
Page 93 and 94: Consolidated Financial Statements 2
Page 95 and 96: C. H. Boehringer Sohn Grundstücksv
Page 97 and 98: C. H. Boehringer Sohn, Ingelheim Co
Page 99 and 100: C. H. Boehringer Sohn, Ingelheim St
Page 101 and 102:
The following subsidiaries were exe
Page 103 and 104:
2 Accounting and evaluation methods
Page 105 and 106:
3 Notes to the consolidated balance
Page 107 and 108:
3.3 Financial assets (in millions o
Page 109 and 110:
Pension provisions Boehringer Ingel
Page 111 and 112:
4 Notes to the consolidated profit
Page 113 and 114:
4.7 Holding income (in millions of
Page 115 and 116:
Other mandatory disclosures accordi
Page 117 and 118:
Derivative financial instruments at
Page 119 and 120:
With the following exception, our a
Page 121 and 122:
Product name Active ingredient Indi
Page 123 and 124:
Animal Health Product name Active i
Page 125 and 126:
Comparison of Balance Sheets/ Finan
show all

Annual Report 2005 - Boehringer Ingelheim

You also want an ePaper? Increase the reach of your titles

Delete template?

Save as template?